[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"National Cheng-Kung University Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":608},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,44,0,25,[9,50,77,104,121,140,162,182,208,231,259,278,297,318,345,372,396,419,439,467,486,510,537,559,586],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":4},"100652794","an-innovative-proprioceptive-instrument-for-upper-extremities-100652794",false,"NCT07779928","An Innovative Proprioceptive Instrument for Upper Extremities","Development, Validation, and Clinical Application of an Innovative Proprioceptive Instrument for Upper Extremities: PropArm-PosiMoF (PropArm)","1. Healthy Young Adults:\n\n   Inclusion Criteria:\n   * (1) Age between 20 and 29 years,\n   * (2) Right-hand dominance, and\n   * (3) Ability to understand three consecutive verbal instructions.\n\n   Exclusion Criteria:\n   * (1) Currently a student or faculty member of the Department of Occupational Therapy at National Cheng Kung University, or a staff member of the Department of Physical Medicine and Rehabilitation, National Cheng Kung University Hospital,\n   * (2) History of surgery on the right upper limb,\n   * (3) Presence of neuromusculoskeletal disorders that may affect sensory or motor function of the right upper limb, such as stroke or shoulder impingement syndrome, and\n   * (4) Uncorrected hearing problems, such as hearing loss.\n2. Healthy Adults:\n\n   Inclusion Criteria:\n   * (1) Age between 30 to 39, 40 to 49, or 50 to 59 years,\n   * (2) Right-hand dominance, and\n   * (3) Ability to understand three consecutive verbal instructions.\n\n   Exclusion Criteria:\n   * (1) Currently a student or faculty member of the Department of Occupational Therapy at National Cheng Kung University, or a staff member of the Department of Physical Medicine and Rehabilitation, National Cheng Kung University Hospital,\n   * (2) History of surgery on the right upper limb,\n   * (3) Presence of neuromusculoskeletal disorders that may affect sensory or motor function of the right upper limb, such as stroke or shoulder impingement syndrome, and\n   * (4) Uncorrected hearing problems, such as hearing loss.\n3. Healthy Older Adults:\n\n   Inclusion Criteria:\n   * (1) Age between 60 to 69, 70 to 79, or 80 to 89 years,\n   * (2) Right-hand dominance, and\n   * (3) Ability to understand three consecutive verbal instructions.\n\n   Exclusion Criteria:\n   * (1) Score below the 5th percentile on the Color Trails Test-Chinese Version (CTT-C),\n   * (2) Currently a student or faculty member of the Department of Occupational Therapy at National Cheng Kung University, or a staff member of the Department of Physical Medicine and Rehabilitation, National Cheng Kung University Hospital,\n   * (3) History of surgery on the right upper limb,\n   * (4) Presence of neuromusculoskeletal disorders that may affect sensory or motor function of the right upper limb, such as stroke or shoulder impingement syndrome, and\n   * (5) Uncorrected hearing problems, such as hearing loss.\n4. Stroke:\n\n   Inclusion Criteria:\n   * (1) Age between 20 and 89 years,\n   * (2) Right-hemispheric hemorrhagic or ischemic stroke with lesions involving proprioceptive pathways or the primary somatosensory cortex, potentially resulting in difficulties with body position, movement, or force perception, or with fine tactile perception (e.g., localization, two-point discrimination, object recognition),\n   * (3) Right-hand dominance, and\n   * (4) Ability to understand three consecutive verbal instructions.\n\n   Exclusion Criteria:\n   * (1) Score below the 5th percentile on the Color Trails Test-Chinese Version (CTT-C),\n   * (2) Upper limb still in acute pain stage,\n   * (3) Muscle tone severe enough to affect right upper limb movement (e.g., score ≥ 1+ on the Modified Ashworth Scale),\n   * (4) Uncorrected hearing problems, such as hearing loss.\n5. Shoulder Impingement Syndrome:\n\n   Inclusion Criteria:\n   * (1) Age between 20 and 89 years,\n   * (2) Diagnosis of shoulder impingement syndrome in the right upper limb,\n   * (3) Right-hand dominance, and\n   * (4) Ability to understand three consecutive verbal instructions.\n\n   Exclusion Criteria:\n   * (1) Score below the 5th percentile on the Color Trails Test-Chinese Version (CTT-C),\n   * (2) Upper limb still in acute pain stage,\n   * (3) Uncorrected hearing problems, such as hearing loss.\n6. Diabetes (DM):\n\nInclusion Criteria:\n\n* (1) Age between 20 and 89 years,\n* (2) Diagnosis of diabetes mellitus by a specialist physician, based on one of the following:\n\n  1. Fasting plasma glucose (FPG) ≥ 126 mg\u002FdL or 7.0 mmol\u002FL;\n  2. Hemoglobin A1C (HbA1c) ≥ 6.5%;\n  3. Plasma glucose ≥ 200 mg\u002FdL or 11.1 mmol\u002FL at 2 hours during an oral glucose tolerance test (OGTT);\n  4. Presence of hyperglycemia symptoms (polyphagia, polyuria, polydipsia, and unexplained weight loss) with a random plasma glucose ≥ 200 mg\u002FdL.\n\nDiagnosis of diabetes is confirmed if any two of items (a-c) are met, or if any one of them remains positive on repeat testing; fulfillment of item (d) alone is also sufficient for diagnosis.\n\n* (3) Right-hand dominance, and\n* (4) Ability to understand three consecutive verbal instructions.\n\nExclusion Criteria:\n\n* (1) Score below the 5th percentile on the Color Trails Test-Chinese Version (CTT-C),\n* (2) History of surgery on the right upper limb,\n* (3) Presence of other neuromusculoskeletal disorders that may affect sensory or motor function of the right upper limb, and\n* (4) Current skin infection, and\n* (5) Uncorrected hearing problems, such as hearing loss.",true,"ALL","20 Years","89 Years",{"count":22,"type":23},280,"ESTIMATED","OBSERVATIONAL","This study aimed to develop and validate an innovative proprioceptive assessment instrument for the upper extremities, the PropArm-PosiMoF (PropArm). This observational study was conducted in three stages. The first stage focused on the development and validation of PropArm, including test-retest reliability, concurrent validity, and convergent validity. The second stage established age norms and cut-off points in healthy adults. In the final stage, PropArm was applied to patients with proprioceptive impairments (stroke, shoulder impingement syndrome, and diabetes mellitus patients) to examine its diagnostic accuracy and clinical applicability.",[27,28,29,30,31,32],"Stroke","Shoulder Impingement Syndrome","Diabetes (DM)","Healthy Young Adults","Healthy Adults","Healthy Older Adults",[34,35,36,37],"Proprioception","Upper Extremities","Instrument","Psychometric Properties","NOT_YET_RECRUITING","2026-08-18",{"date":41,"type":42},"2026-08-21","ACTUAL",{"date":44,"type":23},"2026-09-01",{"date":46,"type":23},"2027-12-31",{"name":48,"class":49},"National Cheng-Kung University Hospital","OTHER",{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":12,"sex":18,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":75,"leadSponsor":76,"locationsCount":4},"100652500","potassium-competitive-acid-blocker-versus-double-dose-proton-pump-inhibitors-in-high-high-risk-peptic-ulcer-bleeding-a-randomized-controlled-trial-100652500","NCT07772700","Potassium-competitive Acid Blocker Versus Double Dose Proton Pump Inhibitors in High High-risk Peptic Ulcer Bleeding","Potassium-competitive Acid Blocker Versus Double Dose Proton Pump Inhibitors in High High-risk Peptic Ulcer Bleeding: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Hospitalized patients \\> 18 years with upper gastrointestinal ulcer bleeding, a Rockall score of 6 or higher, and treatment with endoscopic hemostasis.\n\nExclusion Criteria:\n\n* history of hypersensitivity to PPIs or P-CABs.\n* non-ulcer-related bleeding, such as variceal bleeding, angiodysplasia, diverticular bleeding, diffuse mucosal bleeding, or tumor bleeding.\n* severe hepatic or renal impairment","18 Years",{"count":59,"type":23},108,"INTERVENTIONAL",[62],"NA","This randomized clinical trial will enroll patients at National Cheng Kung University Hospital who have upper gastrointestinal ulcer bleeding, have undergone endoscopic hemostasis, and have a Rockall score of 6 or higher.\n\nA total of 108 patients will be enrolled and randomly assigned to two groups: Standard-treatment group: 54 patients, Experimental group: 54 patients.\n\nBoth groups will receive standard endoscopic hemostasis and 72 hours of intravenous PPI therapy. Thereafter, patients in the standard-treatment group will receive double-dose PPI therapy, whereas patients in the experimental group will receive a P-CAB per day. All patients will be followed for 28 days to assess the occurrence of rebleeding.",[65],"Bleeding",[67,68,69,70,71],"PCAB","PPI","peptic ulcer bleeding","Rockall score","rebleeding",{"date":73,"type":42},"2026-08-20",{"date":44,"type":23},{"date":46,"type":23},{"name":48,"class":49},{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":17,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":60,"phases":87,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},"100652530","the-effect-of-iot-based-smart-exercises-system-in-the-senior-adults-coordination-100652530","NCT07772726","The Effect of IoT-based Smart Exercises System in the Senior Adults: Coordination","Smart Health Care and Innovative Technology Service Model Plan: Development of Innovative Health Promotion System for Senior Adults","Inclusion Criteria:\n\n* Adult over 50 years old\n* No significant limb disability or joint deformation\n* No history of cardiovascular disease\n* Never lost balance due to dizziness in the past 12 months\n\nExclusion Criteria:\n\n* limb disability or joint deformation\n* history of cardiovascular disease\n* lost balance due to dizziness in the past 12 months\n* cognitive deficits","50 Years",{"count":86,"type":23},100,[62],"Subjects are divided into two groups, (1) Control (Ctrl) and (2) Smart Exercise (SE) group. Participants in the Ctrl group are instructed to perform combined muscle strength and coordination exercises twice weekly, with each session lasting 30 minutes, following an exercise guide recommended by a physical therapist. Participants in the SE group perform combined muscle strength and coordination training using the Smart Exercise System twice weekly, with each session lasting 30 minutes, for 12 weeks. Physical fitness tests, coordination tests, and questionnaires are administered to participants in both groups before and after the 12-week exercise program.",[90],"Older Adults",[90,92,93],"Smart Exercises System","Coordination","RECRUITING","2026-08-14",{"date":97,"type":42},"2026-08-19",{"date":99,"type":42},"2023-08-07",{"date":101,"type":23},"2027-08-31",{"name":48,"class":49},1,{"id":105,"slug":106,"hasResults":12,"nctId":107,"briefTitle":108,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":17,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":60,"phases":111,"briefSummary":112,"conditions":113,"keywords":114,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":117,"startDateStruct":118,"completionDateStruct":119,"leadSponsor":120,"locationsCount":103},"100652365","the-effect-of-iot-based-smart-exercises-system-in-the-senior-adults-resistance-band-training-system-100652365","NCT07772713","The Effect of IoT-based Smart Exercises System in the Senior Adults: Resistance Band Training System",{"count":110,"type":23},80,[62],"Subjects are divided into two groups, (1) Control (Ctrl) and (2) Smart Exercise (SE) group. Participants in the Ctrl group are instructed to perform resistance band training twice weekly according to a paper-based exercise guide, whereas participants in the SE group are instructed to perform resistance band training twice weekly for 12 weeks using the Resistance Band Training System. The physical fitness tests and questionnaire of both groups are performed before and after the 12-week exercise program.",[90],[90,115,92,116],"Home-based Training","Physical Function",{"date":97,"type":42},{"date":99,"type":42},{"date":101,"type":23},{"name":48,"class":49},{"id":122,"slug":123,"hasResults":12,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":17,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":60,"phases":129,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":139,"locationsCount":103},"100373093","the-effect-of-iot-based-smart-exercises-system-in-the-senior-adults-100373093","NCT04137939","The Effect of IoT-based Smart Exercises System in the Senior Adults","Smart Health Care and Innovative Technology Service Model Plan : Development of Innovative Health Promotion System for Senior Adults",{"count":128,"type":23},400,[62],"Subjects are divided into two groups, (1) Control (Ctrl) and (2) Smart Exercise (SE) group. Ctrl group are instructed to maintain their daily life. SE participants are instructed to do exercise with smart exercise system twice per week for 12 weeks. The physical fitness tests and questionnaire of both group are performed before and after the 12-week exercise program.",[132],"Elderly Exercise","2026-07-06",{"date":135,"type":42},"2026-07-08",{"date":137,"type":42},"2019-07-15",{"date":101,"type":23},{"name":48,"class":49},{"id":141,"slug":142,"hasResults":12,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":12,"sex":18,"minAge":57,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":60,"phases":149,"briefSummary":150,"conditions":151,"keywords":153,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":159,"completionDateStruct":160,"leadSponsor":161,"locationsCount":4},"100645178","topical-application-of-sucralfate-in-promoting-healing-of-esophageal-ulcers-after-esophageal-varices-ligation-100645178","NCT07679191","Topical Application of Sucralfate in Promoting Healing of Esophageal Ulcers After Esophageal Varices Ligation","Topical Application of Sucralfate in Promoting Healing of Esophageal Ulcers After Esophageal Varices Ligation: A Randomized Controlled Trial","Inclusion Criteria:\n\n* cirrhotic patients aged ≥ 18 years who accept endoscopy for esophageal variceal bleeding\n\nExclusion Criteria:\n\n* no need of endoscopic hemostasis\n* allergy to sucralfate\n* other etiology of bleeding than EV bleeding",{"count":148,"type":23},60,[62],"Patients with EV bleeding often suffered from hematemesis, Tarry stool, and blood loss. Standard treatment for bleeding esophageal varices includes hemodynamic stabilization, pharmacological control, and endoscopic intervention. For endoscopic intervention, endoscopic variceal ligation (EVL) is the first-line therapy with 95% initial hemostasis success rate. However, after variceal ligation, esophageal ulcers form 3 days later. These ulcers expose underlying vessels in friable esophageal mucosa, exacerbated by portal hypertension and coagulopathy in cirrhosis patients. Bleeding peaks around day 5-10 when bands detach. Among these patients, 7-9% of patients experience recurrent bleeding as a result. Recurrent bleeding from esophageal ulcers carries an extremely high mortality rate, particularly in patients with advanced stage cirrhosis. Therefore, how to promote esophageal ulcer healing and prevent ulcer rebleeding is an important clinical issue.\n\nProton pump inhibitors (PPIs) are the primary drugs for preventing and treating gastric ulcers, but clinical evidence for their role in preventing post-ligation esophageal ulcers is insufficient. Sucralfate, a complex of aluminum hydroxide and sucrose octa sulfate, can bind to the wound base. This protective barrier can prevent the wound from further environmental injury. Sucralfate has been widely used for wounds and ulcer treatment, e.g., skin wounds, oral ulcers, and peptic ulcers. Our recent clinical trial also proved topical sucralfate can prevent postpolypectomy bleeding. Therefore, this study aimed to investigate whether the topical administration of sucralfate after standard endoscopic hemostasis can promote the esophageal ulcer healing and reduce the rebleeding event.",[152],"Ulcer Healing",[154,155,156],"Esophageal varices","Post-ligation ulcer","Sucralfate","2026-07-01",{"date":133,"type":42},{"date":157,"type":23},{"date":46,"type":23},{"name":48,"class":49},{"id":163,"slug":164,"hasResults":12,"nctId":165,"briefTitle":166,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":12,"sex":18,"minAge":57,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":60,"phases":169,"briefSummary":170,"conditions":171,"keywords":173,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":179,"completionDateStruct":180,"leadSponsor":181,"locationsCount":4},"100645111","endoscopic-application-of-hemostatic-drug-powder-in-lower-gastrointestinal-bleeding-a-pilot-study-100645111","NCT07679139","Endoscopic Application of Hemostatic Drug Powder in Lower Gastrointestinal Bleeding: A Pilot Study","Inclusion Criteria:\n\n* patients suspect lower gastrointestinal bleeding\n\nExclusion Criteria:\n\n* absence of indication for endoscopic hemostasis\n* known allergy to sucralfate, TXA\n* presence of a hollow organ perforation",{"count":148,"type":23},[62],"This clinical trial will enroll patients at National Cheng Kung University Hospital. All patients who are hospitalized for lower gastrointestinal bleeding and undergo colonoscopy will be invited to participate. This study uses random allocation, with one Intervention group and one Standard group. Both groups will receive standard endoscopic hemostasis. Afterward, patients in the Intervention group will receive local administration of 1.5 g of tranexamic acid and 3 g of sucralfate. Following the endoscopic procedure, patients will be directly observed for 5 minutes to confirm successful hemostasis. All patients will be followed for 28 days to assess the occurrence of post-procedural rebleeding.",[172],"Bleeding After GI Endoscopy",[174,175,176],"lower gastrointestinal bleeding","tranexamic acid","sucralfate","2026-06-25",{"date":157,"type":42},{"date":157,"type":23},{"date":46,"type":23},{"name":48,"class":49},{"id":183,"slug":184,"hasResults":12,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":12,"sex":18,"minAge":189,"maxAge":190,"enrollmentInfo":191,"targetDuration":193,"studyType":24,"phases":4,"briefSummary":194,"conditions":195,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":103},"100641165","an-ai-based-prediction-of-cognitive-capacity-in-older-adults-and-individuals-with-mild-cognitive-impairment-during-virtual-reality-driving-tasks-100641165","NCT07656389","An AI-Based Prediction of Cognitive Capacity in Older Adults and Individuals With Mild Cognitive Impairment During Virtual Reality Driving Tasks","From Eye Movements to Visuomotor Coupling: An AI-Based Prediction of Cognitive Capacity in Older Adults and Individuals With Mild Cognitive Impairment During Virtual Reality Driving Tasks","Inclusion Criteria:\n\n* (1) a score of 23 or higher on the Montreal Cognitive Assessment; (2) a Clinical Dementia Rating score of 0 for cognitively healthy participants or 0.5 for participants with mild cognitive impairment (MCI); (3) healthy young adults aged between 30 and 39 years, and cognitively healthy older adults and participants with MCI aged between 65 and 85 years; (4) right-hand dominance; and (5) adequate visual function to complete VR and eye-tracking tasks, defined as corrected binocular visual acuity of at least 0.5 without severe visual field deficits.\n\nExclusion Criteria:\n\n* (1) the presence or history of major psychiatric disorders or central nervous system diseases; (2) significant ocular diseases, such as untreated cataracts, active retinal diseases, moderate-to-severe or poorly controlled glaucoma, or marked visual field deficits beyond a specified level; (3) epilepsy; and (4) severe dizziness or VR-induced motion sickness.","30 Years","85 Years",{"count":192,"type":23},192,"12 Months","Driving ability in older adults is essential for independent mobility and social participation, yet declines under high cognitive load or distraction often lead to visual attention failures such as \"look-but-fail-to-see,\" increasing crash risk. Older adults and individuals with mild cognitive impairment (MCI) show impairments in visual attention, executive control, and visuomotor integration, which are not adequately captured by conventional assessments. Virtual reality (VR) integrated with eye-tracking and upper-limb motion analysis enables ecologically valid simulation of driving scenarios and precise quantification of visuomotor behavior. However, current studies are limited by single-scenario designs, unimodal AI models, and insufficient integration of action-related data.\n\nThis study proposes a multi-phase framework: Year 1 develops an eye-movement-based AI model for MCI identification; Year 2 integrates multimodal data in VR driving tasks; and Year 3 establishes an explainable AI system with longitudinal validation. The study aims to advance cognitive assessment and develop a digital tool for early MCI detection and driving risk prediction.",[196,197,198,199,90],"Mild Cognitive Impairment (MCI)","Virtual Reality","Eye Movement Disorder","Multimodal Monitoring","2026-06-14",{"date":202,"type":42},"2026-06-18",{"date":204,"type":23},"2026-06-20",{"date":206,"type":23},"2029-12-31",{"name":48,"class":49},{"id":209,"slug":210,"hasResults":12,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":215,"enrollmentInfo":216,"targetDuration":4,"studyType":60,"phases":218,"briefSummary":219,"conditions":220,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":230,"locationsCount":103},"100633363","virtual-reality-mirror-therapy-with-focused-object-directed-attention-system-100633363","NCT07525713","Virtual Reality Mirror Therapy With Focused Object-Directed Attention System","Virtual Reality Mirror Therapy With Focused Object-Directed Attention for Neuro-Rehabilitation","Inclusion Criteria:\n\n* Clinical diagnosis of stroke with unilateral side involved;\n* A score of Mini-mental state examination greater than 24 for proving higher mental function;\n* Time of onset \\> 6 months before treatment begins;\n* Premorbid right-handedness.\n\nExclusion Criteria:\n\n* Severe vision impairment;\n* Major cognitive-perceptual deficit;\n* Other brain disease.","80 Years",{"count":217,"type":23},54,[62],"In this study, the investigators hypothesized that Virtual Reality Mirror Therapy with Focused Object-Directed Attention (VRMTFOA) would yield superior therapeutic effects compared to conventional Virtual Reality Mirror Therapy (VRMT) in individuals with unilateral stroke.\n\nThe aim of this study is to compare the immediate effects of a single session of VRMT, VRMTFOA, and VRMTFOA with auditory feedback on upper extremity function and brain activity in stroke patients.",[27,221,197,222,223,224],"Rehabilitation","Mirror Movement Therapy","Attention","Task Performance",{"date":226,"type":42},"2026-06-16",{"date":228,"type":42},"2026-04-20",{"date":46,"type":23},{"name":48,"class":49},{"id":232,"slug":233,"hasResults":12,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":238,"enrollmentInfo":239,"targetDuration":4,"studyType":60,"phases":241,"briefSummary":243,"conditions":244,"keywords":248,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":253,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":103},"100542278","phase-2-neurotransmitters-in-treatment-resistant-schizophrenia-patients-with-add-on-sodium-benzoate-100542278","NCT06340789","Neurotransmitters in Treatment Resistant Schizophrenia Patients With add-on Sodium Benzoate","Functional Connectivity and Associated Neuropeptides Variations in Treatment Resistant Schizophrenia Patients: Treatment Efficacy of add-on Sodium Benzoate","Inclusion Criteria:\n\n1. Fulfil the DSM5 criteria for schizophrenia or schizoaffective disorder\n2. Research criteria for treatment resistance: little or no symptomatic response to multiple (at least two) antipsychotic treatment of an adequate duration (at least 6 weeks) and adequate doses (equivalent to at least 600 milliequivalent (meq)\u002Fday of chlorpromazine)\n3. 6 month period without remission (i.e. ≥4 item-score for the positive symptoms on PANSS scale , especially delusional thoughts, conceptual disorganisation, excitements, grandiosity, hallucinatory behaviour, excitement, persecution, and hostility)\n4. The persistence of illness was defined as a score of ≥4 (moderately ill) on the severity of illness subscale of the Clinical Global Impression scale (CGI-S), and a lack of stable period of good social occupational function.\n\nExclusion Criteria:\n\n1. Current or previous diagnosis of concurrent DSM-5 disorder due to active medical problems, known neurological disease, or a contraindication to MRI scanning\n2. Current diagnosis of substance-related disorder\n3. Any acute or chronic medical condition\n4. History of head trauma or neurological diseases.","55 Years",{"count":240,"type":23},90,[242],"PHASE2","Although antipsychotic is effective for schizophrenia, however, still certain proportion of patients were not responsive to treatment. Treatment resistant schizophrenia (TRS) is accompanied by function decline and heavy burden. In recent decades, the biological mechanism of schizophrenia extended from dopamine theory to the role of glutamate system. This shift could be an alternative pathway to developing the treatment of TRS. Sodium benzoate (SB) could be an option as a glutamatergic agent for the patients with TRS. However, most evidence of SB is for treating patients with schizophrenia and other mental disorders but the evidence for treating patients with TRS is scarce. To predict the treatment response of SB will be an urgent topic in the future. Little is known about the precise medicine for treating patients with TRS. The present project will extend our pilot randomized clinical trial on SB for TRS. A total of 90 patients with TRS will be enrolled from three centers and will be assigned to 8 weeks of treatment with SB or placebo (2:1). A comprehensive battery of potential markers will be employed, including 1H- magnetic resonance spectroscopy (MRS), brain functional connectivity, genotyping, immune biomarkers, cognitive function, and clinical characteristics. The efficacy of SB on TRS will be confirmed in this project. Predictors for treatment response will be identified. Artificial intelligence algorithms will be used for probing the feasibility of precision medicine.",[245,246,247],"Symptom, Cognitive","Schizophrenia","Schizo Affective Disorder",[249,250,251,252],"schizophrenia","sodium benzoate","cognition","treatment resistant schizophrenia",{"date":226,"type":42},{"date":255,"type":42},"2021-11-18",{"date":257,"type":23},"2028-04-30",{"name":48,"class":49},{"id":260,"slug":261,"hasResults":12,"nctId":262,"briefTitle":263,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":12,"sex":18,"minAge":57,"maxAge":4,"enrollmentInfo":265,"targetDuration":4,"studyType":60,"phases":266,"briefSummary":267,"conditions":268,"keywords":269,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":277,"locationsCount":103},"100634464","endoscopic-application-of-tranexamic-acid-and-sucralfate-in-gastrointestinal-tumor-bleeding-a-randomized-controlled-trial-100634464","NCT07540026","Endoscopic Application of Tranexamic Acid and Sucralfate in Gastrointestinal Tumor Bleeding: A Randomized Controlled Trial","Inclusion Criteria:\n\n* patients aged ≥ 18 years who accept endoscopy for upper GI tumor bleeding\n\nExclusion Criteria:\n\n* patients with no need for endoscopic hemostasis, allergy to sucralfate, tranexamic acid, pregnancy, and patients with hollow organ perforation",{"count":148,"type":23},[62],"Background Gastrointestinal bleeding is a common disease among the population in Taiwan, with gastrointestinal tumor bleeding accounting for 3-5% of cases. The pathophysiology of gastrointestinal tumor bleeding is unique, involving fragile surface mucosa, abnormal vascular proliferation, and malformation, making endoscopic hemostasis challenging. Conventional endoscopic hemostasis methods such as hemostatic injections, clips, or thermal coagulation have suboptimal success rates below 80%, with recurrence rates exceeding 50%. Recent clinical trials have demonstrated that hemostatic powder spraying effectively enhances hemostasis for gastrointestinal ulcers and reduces recurrence rates. Our previous research repurposed tranexamic acid in a powder form to enhance hemostasis for peptic ulcer and applied sucralfate powder to prevent postpolypectomy wound bleeding.\n\nStudy aim Our research team combines previous experience by using tranexamic acid and sucralfate drug powders to spray onto bleeding gastrointestinal tumors to achieve hemostatic effects. Additionally, tumor-derived exosomes are associated with tumor angiogenesis and growth, so we hypothesize that gastrointestinal tumor bleeding may be linked to VEGF and miR-21 expression within gastrointestinal tumor exosomes.\n\nStudy method This study is a clinical randomized controlled trial conducted at National Cheng Kung University Hospital. We will recruit 60 patients with gastrointestinal tumor bleeding undergoing endoscopic hemostasis. Patients in the experimental treatment group will receive additional topical administration of 1.5 g of tranexamic acid and 3 g of sucralfate drug powder. Immediate hemostasis and 30-day bleeding recurrence will be observed. Enrolled patients will also provide blood and tumor specimens for exosome analysis, evaluating the predictive effect of extracted tumor exosomes' VEGF and miR-21 on bleeding risk. This study will explore the association between specific tumor exosome expression levels and bleeding, serving as a basis for bleeding risk assessment and innovative therapies.",[172],[270,271],"Gastric tumor","Tumor bleeding","2026-04-13",{"date":228,"type":42},{"date":275,"type":23},"2026-05-01",{"date":46,"type":23},{"name":48,"class":49},{"id":279,"slug":280,"hasResults":12,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":17,"sex":18,"minAge":57,"maxAge":215,"enrollmentInfo":285,"targetDuration":4,"studyType":60,"phases":286,"briefSummary":287,"conditions":288,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":103},"100603658","effects-of-virtual-reality-multisensory-cooperative-task-oriented-mirror-therapy-100603658","NCT07139379","Effects of Virtual Reality Multisensory Cooperative Task-Oriented Mirror Therapy","Virtual Reality Multisensory Cooperative Task-Oriented Mirror Therapy for Neuro-Rehabilitation","Inclusion Criteria:\n\n* Clinical diagnosis of stroke with unilateral side involved;\n* A score of Mini-mental state examination greater than 24 for proving higher mental function\n* Time of onset \\> 6 months before treatment begins; and\n* Premorbid right-handedness.\n\nExclusion Criteria:\n\n* Severe vision impairment;\n* Major cognitive-perceptual deficit;\n* Other brain disease.",{"count":5,"type":23},[62],"In the proposed study, the investigators assumed that Virtual Reality-Based Generative Bimanual Cooperative Task-Oriented Therapy (VRMCTOMT) will provide a better treatment effects than traditional virtual reality mirror therapy (VRMT) for the patients with unilateral stroke. The aim of the study is to examine the difference in the treatment effects among the combination of task-oriented training with either VRMCTOMT, or VRMT on the upper extremity function and brain activity of the stroke patients.",[27,221,197,222,224],"2026-04-12",{"date":291,"type":42},"2026-04-15",{"date":293,"type":42},"2025-06-24",{"date":295,"type":23},"2026-12-31",{"name":48,"class":49},{"id":298,"slug":299,"hasResults":12,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":304,"targetDuration":4,"studyType":60,"phases":306,"briefSummary":307,"conditions":308,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":103},"100528582","phase-2-total-neoadjuvant-therapy-in-rectal-cancer-100528582","NCT06162650","Total Neoadjuvant Therapy in Rectal Cancer","A Phase II Study of Total Neoadjuvant Therapy in Rectal Cancer","Inclusion Criteria:\n\n* Histologically confirmed diagnosis of adenocarcinoma of the rectum;\n* Tumors located at mid or low rectum (distal extension less than 10 cm from the anal verge);\n* Clinical stage II or III (T3\u002F4 and\u002For N+; no distant metastasis);\n* No prior chemotherapy, radiotherapy or surgery for rectal cancer;\n* Age ≥20;\n* ECOG 0-1;\n* Adequate organ function, including followings:\n\nANC ≥1,500\u002FμL; Hb ≥8.0 gm\u002FdL; Platelet 100,000\u002Fmm3; Total bilirubin ≤1.5x upper normal limit; AST ≤3x upper normal limit; ALT ≤3x upper normal limit; Creatinine ≤1.5x upper normal limit;\n\n* Ability to understand and the willingness to sing a written informed consent.\n\nExclusion criteria\n\n* Recurrent rectal cancer;\n* Patients who have concomitant malignancies, except for adequately treated basal cell carcinoma of the skin or in situ carcinoma of the cervix. Subjects who have prior malignancies and have been disease-free for more than 5 years can be enrolled;\n* Patients who have received prior pelvic radiotherapy;\n* Patients with active infection requiring intravenous antibiotic treatment;\n* Patients with a history of any arterial thrombotic event within the past 6 months, including unstable angina, myocardial infarction (MI) or cerebrovascular accident (CVA), New York Hear Association (NYHA) grade II or greater congestive heart failure, or uncontrolled cardiac arrhythmia;\n* Patients with any other concurrent medical or psychiatric condition or disease which, in the investigator's judgement, would make them inappropriate candidates for entry into this study;\n* Women who are pregnant or breastfeeding. Women of childbearing potential who are unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period;\n* Patients receiving other anticancer or experimental therapy;\n* Known DPD deficiency or hypersensitivity to oxaliplatin;\n* Any contraindications to MRI.",{"count":305,"type":23},42,[242],"In this phase 2 study, the efficacy of total neoadjuvant therapy in Taiwanese patients with rectal cancer will be investigated. Patients with stage II or III middle\u002Flow rectal cancer will be prospective enrolled. The total neoadjuvant therapy with the short-course radiotherapy (5×5 Gy over a maximum of 8 days) followed by chemotherapy with mFOLFOX6 for 9 cycles will be administered. The primary endpoint is the complete response (CR) rate which will take into account the patients with clinical and pathological complete response.",[309],"Rectal Cancer","2026-04-07",{"date":312,"type":42},"2026-04-08",{"date":314,"type":42},"2023-11-16",{"date":316,"type":23},"2030-11-16",{"name":48,"class":49},{"id":319,"slug":320,"hasResults":12,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":4,"eligibilityCriteria":324,"healthyVolunteers":12,"sex":18,"minAge":57,"maxAge":215,"enrollmentInfo":325,"targetDuration":4,"studyType":60,"phases":327,"briefSummary":328,"conditions":329,"keywords":331,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":103},"100621334","continuous-cervical-erector-spinae-plane-block-versus-interscalene-nerve-block-in-shoulder-arthroscopic-surgery-100621334","NCT07369271","Continuous Cervical Erector Spinae Plane Block Versus Interscalene Nerve Block in Shoulder Arthroscopic Surgery","Continuous Cervical Erector Spinae Plane Block Versus Interscalene Nerve Block in Shoulder Arthroscopic Surgery- A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adult patients scheduled for elective shoulder arthroscopic surgery\n\nExclusion Criteria:\n\n* Contraindications to regional analgesia\n* BMI \\>40\n* ASA physical status IV\n* history of drug or opioid abuse\n* preoperative upper limb motor impairment\n* postoperative ventilator support or ICU admission\n* Inability to provide self-reported pain assessments",{"count":326,"type":23},165,[62],"Shoulder arthroscopic surgery is associated with moderate to severe postoperative pain, which may hinder early mobilization and functional recovery. Interscalene block (ISB) is commonly used to provide effective analgesia but is frequently associated with hemidiaphragmatic paralysis due to phrenic nerve involvement. Cervical erector spinae plane block (ESPB) has been proposed as an alternative regional technique that may provide analgesia while reducing respiratory-related adverse effects. This randomized controlled trial aims to compare the analgesic efficacy and safety of cervical ESPB versus continuous ISB in patients undergoing shoulder arthroscopic surgery.",[330],"Shoulder Arthroscopy",[332,333,334,335,336],"Shoulder arthroscopy","postoperative pain","regional anesthesia","interscalene block","erector spinae plane block","2026-01-17",{"date":339,"type":42},"2026-01-27",{"date":341,"type":23},"2026-01-15",{"date":343,"type":23},"2028-01-31",{"name":48,"class":49},{"id":346,"slug":347,"hasResults":12,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":4,"eligibilityCriteria":351,"healthyVolunteers":17,"sex":18,"minAge":57,"maxAge":352,"enrollmentInfo":353,"targetDuration":4,"studyType":60,"phases":355,"briefSummary":356,"conditions":357,"keywords":360,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":103},"100619158","effectiveness-of-the-safe-haven-application-app-among-undergraduates-100619158","NCT07340983","Effectiveness of the Safe Haven Application (App) Among Undergraduates","The Effectiveness of the Safe Haven APP on Mental Health Among Undergraduates: A Randomized Controlled Trial","Inclusion Criteria:\n\n* registered undergraduates aged 18-24 years\n* own a personal smart device (mobile phone or tablet)\n* ability to read Chinese\n* willingness to install the study app and complete the follow-up assessments.\n\nExclusion Criteria:\n\n* are on leave of absence or not officially enrolled during the study period\n* are participating in another mental health intervention program or using similar mental health apps.","24 Years",{"count":354,"type":23},68,[62],"The goal of this randomized controlled trial is to evaluate the effectiveness of the Safe Haven app in reducing mental health symptoms and enhancing mental health literacy in undergraduates at a national university in southern Taiwan. The main questions it aims to answer are:\n\nDoes the Safe Haven app lead to significantly greater reductions in general psychological distress, depression, anxiety, and stress compared to standard campus care?\n\nDoes the app result in greater improvements in mental health literacy among participants?\n\nResearchers will compare an experimental group (receiving the Safe Haven app in addition to standard campus care) to a waitlist control group (receiving standard campus care only) to see if the intervention provides superior improvements in mental health outcomes over time.\n\nParticipants will:\n\nComplete online assessments at three time points: baseline (T0), post-intervention (3 months, T1), and follow-up (3 months post-intervention, T2).\n\nExperimental Group: Download the Safe Haven app to complete daily mood self-monitoring and weekly assessments, and receive psychoeducational content, personalized suggestions for 3 months.\n\nControl Group: Maintain access to standard campus care and receive access to the app after the final follow-up assessment.",[358,359],"Depression","Anxiety",[361,362,363,364],"undergraduates","mental health","app","mental health literacy",{"date":366,"type":42},"2026-01-21",{"date":368,"type":42},"2025-09-16",{"date":370,"type":23},"2027-01-31",{"name":48,"class":49},{"id":373,"slug":374,"hasResults":12,"nctId":375,"briefTitle":376,"officialTitle":376,"acronym":4,"eligibilityCriteria":377,"healthyVolunteers":12,"sex":18,"minAge":57,"maxAge":4,"enrollmentInfo":378,"targetDuration":4,"studyType":60,"phases":380,"briefSummary":382,"conditions":383,"keywords":384,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":395,"locationsCount":4},"100612772","phase-4-prevention-of-delayed-post-polypectomy-bleeding-by-endoscopic-sucralfate-spray-in-high-risk-patients-a-randomized-controlled-trial-100612772","NCT07257926","Prevention of Delayed Post-polypectomy Bleeding by Endoscopic Sucralfate Spray in High-risk Patients: A Randomized Controlled Trial","Inclusion Criteria:\n\n* patients who take antiplatelets or anticoagulants with large polyps (size ≥ 1 cm)\n\nExclusion Criteria:\n\n* lacked complete data (serum creatinine, platelet count, and prothrombin time) pertaining to the previous 6 months\n* those who did not discontinue or inadequately discontinued antiplatelet agents or anticoagulants\n* those who had a known allergy to sucralfate",{"count":379,"type":23},160,[381],"PHASE4","Background： Colonoscopy can detect colon polyps and perform excision to the polyps to prevent colon cancer. However, delayed polypectomy bleeding is one of the complications to be noticed, which has an occurrence rate of about 1-2%, especially large polyps over 1cm with hot snare polypectomy. Colonoscopic clipping was applied for the treatment of bleeding. However, prophylactic clipping after polypectomy was not proved to reduce the rate of delayed polypectomy bleeding. Sucralfate is used for peptic ulcer treatment, which can become a protective layer on the wound to prevent environmental injury. Our preliminary data revealed the endoscopic sucralfate spray could reduce the delayed bleeding rate among general populations. Whether sucralfate can prevent polypectomy wounds from delayed bleeding in high-risk polyps is unknown.\n\nAim： This study aimed to compare the efficacy in reducing delayed bleeding rate between sucralfate administration and prophylactic clipping on high-risk polypectomy wounds.\n\nMethod： This is a randomized clinical trial. The study will recruit 160 patients. After randomization, 80 patients will be classified into the Sucralfate group and 80 into the Clipping group. The participants will receive an endoscopic survey as routine, and we will enroll all patients who take antiplatelets or anticoagulants with polyp size ≥ 1 cm after hot snare polyp excision. Exclusion criteria include patients with an allergy to sucralfate. If immediate polypectomy bleeding occurs, we will apply standard endoscopic therapy by either local injection of diluted epinephrine, heater probe coagulation, and\u002For hemoclipping. After then, we will spray 3g of sucralfate powder through colonoscopy precisely on the polypectomy wound in the Sucralfate group, and prophylactic clipping will be placed on the polypectomy wound in the Clipping group. All enrolled patients will be monitored for delayed bleeding for 28 days after the colonoscopy.\n\nExpected results and clinical importance:\n\nThis study is expected to find that the use of sucralfate powder can more effectively reduce the bleeding risk in high-risk wounds compared to prophylactic clips. In addition to promoting the implementation of national health policies and reducing public exposure to the risk of complications, it can also help avoid medical expenses resulting from complications.",[172],[385,176,386,387,388],"polypectomy","antiplatelet","anticoagulant","postpolypectomy bleeding","2025-12-01",{"date":391,"type":42},"2025-12-02",{"date":393,"type":23},"2025-12-15",{"date":46,"type":23},{"name":48,"class":49},{"id":397,"slug":398,"hasResults":12,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":4,"eligibilityCriteria":402,"healthyVolunteers":17,"sex":18,"minAge":57,"maxAge":4,"enrollmentInfo":403,"targetDuration":4,"studyType":60,"phases":405,"briefSummary":406,"conditions":407,"keywords":409,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":412,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":103},"100599328","phase-4-precise-endoscopic-application-of-nitroglycerin-in-preventing-post-ercp-pancreatitis-100599328","NCT07083063","Precise Endoscopic Application of Nitroglycerin in Preventing Post-ERCP Pancreatitis","Precise Endoscopic Application of Nitroglycerin in Preventing Post-ERCP Pancreatitis: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Eligible participants include patients aged ≥ 18 years who accept ERCP and sphincterotomy for common bile duct (CBD) stone extraction.\n\nExclusion Criteria:\n\n* patients with pancreatic cancer\n* shock status (systolic blood pressure \\\u003C 90 mmHg or using inotropic agents)\n* allergy to NTG\n* angle-closure glaucoma\n* severe anemia\n* patients on PDE 5 inhibitors",{"count":404,"type":23},440,[381],"Endoscopic retrograde cholangiopancreatography (ERCP) is a technically demanding procedure combining endoscopy and fluoroscopy to diagnose and treat pancreaticobiliary disorders such as bile duct stones, strictures, and cholangitis. Despite its therapeutic value, ERCP carries a relatively high complication risk of about 10%, with severe complications occurring in roughly 24% of those affected and mortality rates between 0.2% and 0.7%. The most common and significant complication is post-ERCP pancreatitis (PEP), occurring in 2% to 10% of average patients and up to 40% or higher in high-risk groups. PEP ranges from mild, self-limiting inflammation to severe, life-threatening conditions including pancreatic necrosis and multi-organ failure.\n\nPEP arises from mechanical trauma, hydrostatic injury, chemical irritation, or infection during ERCP that activates inflammatory pathways within the pancreas. Key patient-related risk factors include young age, female sex, prior pancreatitis, and sphincter of Oddi dysfunction; procedural factors include difficult biliary cannulation, pancreatic duct manipulation, and precut sphincterotomy.\n\nPreventive strategies focus on minimizing mechanical injury and pharmacologic prophylaxis. Rectal NSAIDs (indomethacin, diclofenac) administered immediately before ERCP are well-supported for reducing PEP risk. Periprocedural aggressive intravenous hydration and prophylactic pancreatic duct stenting in high-risk cases also lower PEP incidence.\n\nNitroglycerin, a smooth muscle relaxant acting via nitric oxide-mediated sphincter relaxation, has shown promise in PEP prevention, especially in patients contraindicated for NSAIDs. Clinical trials indicate that transdermal or sublingual nitroglycerin reduces PEP rates, and combined use with NSAIDs may enhance protection. However, current guidelines do not routinely recommend nitroglycerin due to limited consensus on its efficacy.\n\nTopical nitroglycerin, known to relax smooth muscles locally and used in anorectal conditions, might reduce sphincter of Oddi pressure without systemic side effects. This suggests potential benefit in lowering PEP incidence or severity when applied topically during ERCP, pending further investigation. This study aimed to investigate whether topical delivery of nitroglycerin can reduce the incidence rate of PEP or the severity of pancreatitis.",[408],"Pancreatitis",[410,411],"post-ERCP pancreatitis","nitroglycerin",{"date":413,"type":42},"2025-12-08",{"date":415,"type":42},"2025-09-15",{"date":417,"type":23},"2027-07-31",{"name":48,"class":49},{"id":420,"slug":421,"hasResults":12,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":4,"eligibilityCriteria":425,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":426,"targetDuration":4,"studyType":60,"phases":428,"briefSummary":429,"conditions":430,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":438,"locationsCount":103},"100612472","precision-health-and-smart-telerehabilitation-in-osa-100612472","NCT07254026","Precision Health and Smart Telerehabilitation in OSA","Developing a Precision Health Approach for Obstructive Sleep Apnea: Treatment Responses Analysis and Smart Telerehabilitation Systems","Inclusion Criteria:\n\n* 20 years old and above\n* Newly diagnosed with mild to severe pure obstructive sleep apnea based on polysomnography\n\nExclusion Criteria:\n\n* Severe allergic rhinitis\n* Sinusitis with nasal polyps\n* Body Mass Index (BMI) \\> 31\n* Alcohol or drug abuse within the past year\n* Pregnancy\n* Severe obstructive or restrictive pulmonary diseases\n* High-risk cardiovascular diseases during exercise (e.g., angina, myocardial infarction, heart failure, valvular heart disease)\n* History of central or peripheral neurological disorders that interfere with exercise prescription\n* Musculoskeletal or psychological disorders that interfere with exercise prescription\n* Other non-respiratory sleep disorders\n* Sleep disorders with concomitant central sleep apnea",{"count":427,"type":23},300,[62],"This study aims to improve treatment strategies for Obstructive Sleep Apnea (OSA), a disorder characterized by recurrent upper airway collapse during sleep, resulting in reduced oxygenation, sleep fragmentation, and excessive daytime sleepiness. The objectives are twofold: to evaluate whether an artificial intelligence (AI)-based model can accurately predict the most effective treatment for individual patients, and to assess whether a mobile health application can enhance adherence to oropharyngeal rehabilitation (OPR) and improve therapeutic outcomes.\n\nThe study will be conducted in two phases. In Phase I, a retrospective analysis will be performed using a large dataset of polysomnography (PSG) records obtained from the Sleep Center at National Cheng Kung University Hospital. Machine learning algorithms will be applied to identify predictive features that differentiate responders from non-responders across Continuous Positive Airway Pressure (CPAP), surgical, and OPR interventions. These findings will inform the development of a predictive treatment recommendation model.\n\nIn Phase II, a prospective clinical trial will validate the predictive accuracy and clinical utility of the model. Patients newly diagnosed with OSA will be assigned to CPAP, surgery, or OPR interventions according to the model's recommendations, in combination with physician judgment and patient preference. Each intervention will last 12 weeks, followed by repeat PSG and clinical assessments. Within the OPR arm, participants will be further randomized to monitor adherence via an exercise diary or a smartphone application equipped with a pressure sensor and facial motion recognition technology, enabling real-time feedback and remote monitoring.\n\nThis trial is expected to determine whether AI can provide clinically reliable treatment recommendations and whether digital telerehabilitation can improve adherence and outcomes, thereby advancing precision medicine in OSA management.",[431],"Obstructive Sleep Apnea","2025-11-19",{"date":434,"type":42},"2025-11-28",{"date":436,"type":42},"2025-10-15",{"date":206,"type":23},{"name":48,"class":49},{"id":440,"slug":441,"hasResults":12,"nctId":442,"briefTitle":443,"officialTitle":444,"acronym":4,"eligibilityCriteria":445,"healthyVolunteers":12,"sex":446,"minAge":447,"maxAge":4,"enrollmentInfo":448,"targetDuration":4,"studyType":60,"phases":450,"briefSummary":451,"conditions":452,"keywords":455,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":460,"startDateStruct":462,"completionDateStruct":464,"leadSponsor":466,"locationsCount":103},"100611626","ultrasound-and-electromyography-biofeedback-for-pelvic-floor-muscle-training-100611626","NCT07243028","Ultrasound and Electromyography Biofeedback for Pelvic Floor Muscle Training","Application of Simultaneous Pelvic Floor Ultrasonography and Electromyography Biofeedback on Pelvic Floor Muscle Training","Inclusion Criteria:\n\n1. Women aged 21 years or older diagnosed with pelvic floor muscle dysfunction and requiring pelvic floor muscle training (e.g., for symptomatic pelvic organ prolapse, stress urinary incontinence, or dysfunctional voiding).\n2. A Pelvic Floor Disability Index (PFDI-20) score greater than 1.\n3. Ability and willingness to provide written informed consent and authorization for the release of personal health information.\n4. Willingness and ability to complete all required questionnaires\n\nExclusion Criteria:\n\n1. Individuals planning a future pregnancy.\n2. Inability to read, understand, or sign the written consent form prior to participation.","FEMALE","21 Years",{"count":449,"type":23},70,[62],"This study aims to investigate the factors influencing adherence to pelvic floor muscle training (PFMT) devices among patients with pelvic floor dysfunction (PFD) through structured questionnaires, while simultaneously comparing the effectiveness of different feedback modalities, including non-invasive ultrasound imaging and invasive manometry with electromyography (EMG). By integrating subjective adherence data with objective performance outcomes, the project seeks to evaluate the potential of system-level integration for personalized therapeutic strategies, ultimately enhancing treatment efficacy, improving patient satisfaction, and promoting sustained engagement in PFMT.",[453,454],"Pelvic Floor Dysfunction","Pelvic Floor Muscle Weakness",[456,457,458,459],"Pelvic floor dysfunction","Pelvic floor muscle training","Health behavior","Biofeedback",{"date":461,"type":42},"2025-11-21",{"date":463,"type":42},"2024-02-29",{"date":465,"type":23},"2028-12-31",{"name":48,"class":49},{"id":468,"slug":469,"hasResults":12,"nctId":470,"briefTitle":471,"officialTitle":472,"acronym":4,"eligibilityCriteria":473,"healthyVolunteers":17,"sex":446,"minAge":57,"maxAge":215,"enrollmentInfo":474,"targetDuration":4,"studyType":60,"phases":476,"briefSummary":477,"conditions":478,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":480,"startDateStruct":482,"completionDateStruct":484,"leadSponsor":485,"locationsCount":103},"100604061","investigating-the-correlation-between-pre-treatment-imaging-derived-body-composition-chemotherapy-dose-adjustment-and-treatment-efficacy-in-gynecological-cancer-patients--100604061","NCT07144618","Investigating the Correlation Between Pre-Treatment Imaging-Derived Body Composition, Chemotherapy Dose Adjustment, and Treatment Efficacy in Gynecological Cancer Patients \"","A Multicenter Ambidirectional Study Investigating the Association Between Pre-Treatment Imaging-Derived Body Composition, Chemotherapy Dose Adjustment, and Treatment Efficacy in Patients With Endometrial and Ovarian Cancer","Inclusion Criteria\n\n1. Able to comprehend and willing to participate in this clinical trial, with signed informed consent.\n2. Underwent an abdominal computed tomography (CT) scan within three months prior to surgical treatment, with a non-contrast-enhanced single-slice image at the third lumbar vertebral level available for body composition analysis.\n3. Histologically or cytologically confirmed diagnosis of endometrial cancer or ovarian cancer.\n4. Age between 20 and 80 years.\n5. Good performance status (ECOG performance status of 0, 1, or 2).\n6. Adequate hematologic parameters:\n\n   * Hemoglobin ≥10 g\u002FdL\n   * White blood cell count ≥3,000\u002FμL\n   * Neutrophil count ≥1,500\u002FμL\n   * Platelet count ≥100,000\u002FμL\n7. Adequate organ function:\n\n   * Total bilirubin ≤1.5 times the upper limit of normal (ULN).\n   * Alanine aminotransferase (ALT) \u002F Aspartate aminotransferase (AST) ≤2.5 times ULN (≤5.0 times ULN for patients with liver metastases).\n   * Creatinine ≤ ULN. Exclusion Criteria\n\n1\\. Presence of other major diseases that may be exacerbated by chemotherapy (e.g., autoimmune diseases).\n\n2\\. History of other malignancies within the past two years before trial enrollment, except for adequately treated non-melanoma skin cancer, stage 0 cervical carcinoma, or ductal carcinoma in situ of the breast.\n\n3\\. Requirement for concurrent treatment of unrelated diseases during the trial period, including chemotherapy, radiotherapy, or investigational drugs.\n\n4\\. Mental status deemed unsuitable for participation in the clinical trial. 5. Expected survival time of less than six months. 6. Poor-quality abdominal CT images, clearly attributable to the following causes:\n\n* Motion artifacts due to poor patient compliance.\n* Noticeable scoliosis or kyphosis.\n* Multiple lumbar vertebral compression fractures.\n* Significant generalized edema.\n* Presence of metallic implants in the lumbar spine or abdomen.\n* Abdominal stoma or significant abdominal wall defects.\n* Marked asymmetry or localized atrophy\u002Fdeficiency of the core abdominal musculature.",{"count":475,"type":23},294,[62],"The dosage of paclitaxel, an adjuvant chemotherapy agent for endometrial and ovarian cancer, is typically calculated based on the patient's body surface area (BSA). However, cancer patients with the same BSA may exhibit significant differences in body composition, which could influence the distribution pattern of paclitaxel in the body. These variations may lead to individual differences in drug tolerance and adverse effects. Such variability not only impacts the patient's treatment experience and quality of life but may also increase medical costs, including hospitalization, emergency department visits, and additional treatments required to manage chemotherapy-induced toxicities.\n\nOur preliminary study results indicate that skeletal muscle area (SMA) and skeletal muscle index (SMI), as assessed through computed tomography (CT) imaging, are significantly associated with the incidence of Grade 3 or higher leukopenia or neutropenia following the first two cycles of chemotherapy in patients with endometrial cancer. Furthermore, the predictive accuracy of these CT-derived muscle measurements surpasses the clinical judgment made by physicians based on conventional treatment guidelines. Patients who develop Grade 3 or higher leukopenia or neutropenia during the first two cycles are more likely to experience more frequent occurrences of Grade 3 or higher chemotherapy-related adverse effects in subsequent treatment cycles.\n\nHowever, no study has comprehensively investigated the relationship between body composition, chemotherapy dosing, and adverse effects. Therefore, this trial aims to examine the impact of body composition on chemotherapy dose adjustments and adverse effects. By utilizing body composition data extracted from abdominal CT imaging through this product, this study seeks to establish a risk stratification tool to assist physicians in treating patients with endometrial and ovarian cancer by providing a reference for chemotherapy dose reduction.\n\nIt is expected that through a precision chemotherapy strategy, the incidence of chemotherapy-related adverse effects can be reduced, thereby lowering medical resource expenditures incurred from managing these adverse effects, such as emergency department visits, hospitalizations, additional diagnostic tests, and supportive medication costs. Furthermore, this approach aims to improve patients' health-related quality of life and achieve a dual benefit of medical economic efficiency and clinical effectiveness.",[479],"Search MeSH",{"date":481,"type":42},"2025-09-22",{"date":483,"type":23},"2025-09",{"date":465,"type":23},{"name":48,"class":49},{"id":487,"slug":488,"hasResults":12,"nctId":489,"briefTitle":490,"officialTitle":491,"acronym":4,"eligibilityCriteria":492,"healthyVolunteers":12,"sex":18,"minAge":57,"maxAge":493,"enrollmentInfo":494,"targetDuration":4,"studyType":60,"phases":496,"briefSummary":498,"conditions":499,"keywords":501,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":504,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":509,"locationsCount":103},"100556924","phase-1-establishing-best-treatment-strategy-for-t4-esophageal-cancer-100556924","NCT06531434","Establishing Best Treatment Strategy for T4 Esophageal Cancer","A Pilot Study to Establish Best Treatment Strategy for T4 Esophageal Cancer","Inclusion Criteria:\n\n1. Histologically confirmed esophageal squamous cell carcinoma\n2. Tumor or lymph nodes invade adjacent organs (T4 stage)\n3. Aged between 18-70 years old\n4. Patient health status score Eastern Cooperative Oncology Group (ECOG) performance status (PS) \\\u003C2\n5. Hemoglobin ≥ 10 g\u002FL, absolute neutrophil count ≥ 2×10\\^3\u002FL, platelet count ≥ 100×10\\^9\u002FL, total bilirubin ≤ 1.5 mg\u002FL, serum transaminases ≤ 105 U\u002FL, creatinine clearance ≥ 40 mL\u002Fmin.\n\nExclusion Criteria:\n\n1. Previous chemotherapy history\n2. Myocardial infarction within the last three months\n3. History of unstable angina, interstitial pneumonia, fibrotic lung disease, or severe emphysema\n4. Has other malignancies currently\n5. Uncontrolled infection\n6. Pregnancy or lactation\n7. Perforated esophagus at the time of diagnosis","70 Years",{"count":495,"type":23},22,[497,242],"PHASE1","The goal of this clinical trial is to investigate the safety and efficacy of a new treatment approach for T4-stage esophageal cancer, which involves chemoradiotherapy after induction chemotherapy. The main questions it aims to answer are:\n\n* Does the new induction chemotherapy followed by chemoradiation reduce esophageal perforation rate?\n* Does the new induction chemotherapy followed by chemoradiation increase treatment response rate and patient survival? Researchers will analyze the above data to see if the new treatment approach works to treat T4 esophageal cancer.\n\nParticipants will:\n\n* Receive induction chemotherapy for 4 to 8 cycles, followed by chemoradiation therapy if downstage to T3\n* Visit the clinic once every week for checkups and tests\n* Keep a diary of their symptoms",[500],"Esophageal Cancer TNM Staging Primary Tumor (T) T4",[502,503],"T4 esophageal cancer","Induction chemotherapy",{"date":481,"type":42},{"date":506,"type":42},"2024-08-01",{"date":508,"type":23},"2026-04-30",{"name":48,"class":49},{"id":511,"slug":512,"hasResults":12,"nctId":513,"briefTitle":514,"officialTitle":514,"acronym":4,"eligibilityCriteria":515,"healthyVolunteers":17,"sex":18,"minAge":516,"maxAge":215,"enrollmentInfo":517,"targetDuration":4,"studyType":60,"phases":518,"briefSummary":519,"conditions":520,"keywords":522,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":530,"startDateStruct":532,"completionDateStruct":534,"leadSponsor":536,"locationsCount":103},"100598897","innovative-hand-rehabilitation-system-with-synchronized-contralateral-haptic-feedback-100598897","NCT07077460","Innovative Hand Rehabilitation System With Synchronized Contralateral Haptic Feedback","Inclusion Criteria:\n\n* Age ranged from 20-80 years old\n* Without past medical history of musculoskeletal or neurological disorders that would affect muscle control ability or cause sensory abnormalities\n* Normal cognitive function to understand and follow the instructions\n* Able to understand Chinese, English, or Taiwanese language\n\nExclusion Criteria:\n\n* With a history of hand-related surgeries\n* With a history of neuromuscular diseases or degenerative arthritis\n* With a history of brain injury\n* With a history of taking psychiatric medications\n* Unable to understand instructions, or have cognitive impairments\n* With a history of physical disabilities (Loss of body parts) or taking relevant medications, including heart disease, peripheral arterial disease, respiratory system diseases, dialysis, unresolved upper extremity injury, or highly addicted to smoking or alcohol","60 Years",{"count":86,"type":23},[62],"Previous studies have found that graded motor imagery (GMI) training can provide continuous activation of the cerebral cortex compared to traditional rehabilitation therapy. One of the steps in this strategy, mirror therapy, has also been widely used in the clinical treatment of hemiplegic patients. Also, comparing with traditional rehabilitation treatments, mirror therapy can continuously provide cortical activation. Besides, several studies indicated that game-based interventions contribute to brain activation in the elderly due to their interest can improve users' motivation in the training program execution. In addition, force control training has positive effects on hand dexterity, and specific doses of motor control training not only improve motor function but also have positive effects on brain function.\n\nCurrently, hand function training primarily focuses on range of motion, strength, and hand function, although there is comparatively less emphasis on enhancing both force control and brain function. Moreover, studies related to mirror therapy has primarily focused on the execution of functional movements, but has not explored whether hand strength control training can achieve the same training effects on the affected or non-dominant side through the concept of mirror therapy. Furthermore, the effects of combining a hand strength control system with a synchronous contralateral clip-on force feedback device on brain activation and hand function have not yet been studied. Therefore, this study aimed to investigate the effects of integration a finger force control training system with synchronous contralateral force feedback and mirror visual feedback device on brain activation and hand function, aiming to develop a clinically applicable hand rehabilitation system. Additionally, visual feedback from force control training in our study is through the hints displayed virtually on the game interface of the tablet, which were represented as the height of the targets, not as typical as actual movement-based mirror therapy or task-based mirror therapy.\n\nTherefore, the purpose of the study is to understand the differences among training effects of integrating Graded-Pressure Haptic Device-TiPR closed-loop system and MVF; MVF and force control training, as well as isolated force control training, and to explore the training effects on hand strength, hand function and brain activation.",[521],"Healthy Elderly",[523,524,525,526,527,528],"Functional near infrared spectroscopy","Parameters of digit force independence","Mirror Visual Feedback","Hand Training System","Hand Dexterity","Synchronized contralateral haptic feedback","2025-08-24",{"date":531,"type":42},"2025-08-29",{"date":533,"type":42},"2024-10-04",{"date":535,"type":23},"2025-10-22",{"name":48,"class":49},{"id":538,"slug":539,"hasResults":12,"nctId":540,"briefTitle":541,"officialTitle":542,"acronym":4,"eligibilityCriteria":543,"healthyVolunteers":17,"sex":18,"minAge":57,"maxAge":190,"enrollmentInfo":544,"targetDuration":4,"studyType":60,"phases":545,"briefSummary":546,"conditions":547,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":551,"lastUpdatePostDateStruct":552,"startDateStruct":554,"completionDateStruct":556,"leadSponsor":558,"locationsCount":103},"100527735","a-novel-multisensory-rhythmic-intervention-in-geriatric-rehabilitation-100527735","NCT06151626","A Novel Multisensory-Rhythmic Intervention in Geriatric Rehabilitation","Linking From an Artificial-Intelligence Driven Assessment of Upper Extremity Motor Adaptation to a Novel Multisensory-Rhythmic Intervention in Geriatric Rehabilitation","Inclusion Criteria:\n\n1. Montreal Cognitive Assessment (MoCA) score of 23 or higher,\n2. Clinical Dementia Rating (CDR) of 0 (for normal subjects) or 1 (for mild cognitive impairment subjects),\n3. Healthy young participants aged between 20-39 years, healthy older adults and mild cognitive impairment participants aged between 65-85 years,\n4. No skeletal, muscular, or neurological problems in the upper limbs in the past year, and\n5. Sufficient visual acuity to complete the tasks.\n\nExclusion Criteria:\n\n* Any subjects with significant mental illness, central nervous system disorders, or medical history",{"count":59,"type":23},[62],"Human performance takes shape from the dynamic interaction between person, environment, and task. Goal-directed action is a complex task, which requires the elderly to adapt their motor response according to the environment constraints and task requirements to accomplish the task goal. Among age-related problems, motor control deficits are often the main problems which restricts the frail elderly from maintaining independence for activities of daily living. Therefore, to preserve the quality of life, motor function of the elderly must be taken into consideration, including early detection of motor control problems and development of appropriate intervention strategy for persons with either healthy or pathological brain aging. Rhythmic skill training which is a new mode of dual tasks using rhythmic cueing as an external agent for facilitating an automatized motor task. During training, rhythmic skill training can provide multi-component of sensory stimulation, strengthen motor planning and optimize motor execution, therefore, it will improve the motor performance for the elderly or patients with mild cognitive impairment. In addition, the neuroplastic changes related to sensory processing, selective attention, or working memory demands through music rhythm training can facilitate the cognitive function for the elderly which is a current trend of geriatric rehabilitation. Moreover, the advantage of virtual reality is that it provides important information related to knowledge of result, which can induce better motor and cognitive training effects. Therefore, this research project will focus on assessing and intervening motor adaptation of upper extremity for the healthy elderly and patients with mild cognitive impairment. The first purpose of the project will analyze the difference in efficiency of responsive and predictive grasping motor adaptation among the healthy young adults, healthy elderly and patients with mild cognitive impairment through a test of perturbation-based of pinch-holding-up-activity, and use artificial intelligence for more accurate classification for the grasp pattern of healthy young adults, elderly and patients with mild cognitive impairment. The second one is to verify the effects of virtual-reality based rhythmic skill training system on the motor adaptation capability of upper limb and cognition for the elderly and patients with mild cognitive impairment.",[197,548,549,550],"Hand Mirror","Geriatric","Kinesiology, Applied","2025-08-15",{"date":553,"type":42},"2025-08-21",{"date":555,"type":42},"2023-12-05",{"date":557,"type":23},"2026-12",{"name":48,"class":49},{"id":560,"slug":561,"hasResults":12,"nctId":562,"briefTitle":563,"officialTitle":564,"acronym":565,"eligibilityCriteria":566,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":567,"targetDuration":4,"studyType":60,"phases":569,"briefSummary":570,"conditions":571,"keywords":574,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":580,"startDateStruct":582,"completionDateStruct":584,"leadSponsor":585,"locationsCount":103},"100602071","ahcc-as-immune-modulator-in-cancer-patients-treated-with-immunotherapy-100602071","NCT07118735","AHCC® as Immune Modulator in Cancer Patients Treated With Immunotherapy","A Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) as Immune Modulator in Cancer Patients Treated With Immunotherapy: a Phase 2 Double-blind, Randomized, Placebo-controlled Trial","NCKUH","Inclusion Criteria:\n\n* 1.Liver cancer patient who will receive immunotherapy\n* 2.At least one measurable tumor, according to RECIST version 1.1, that has not been treated with any local procedure.\n* 3.Age \\>=20 years old.\n* 4.ECOG performance status 0 or 1.\n* 5.White blood count \\>=2,000\u002Fmicroliter ; platelet count \\>=60,000\u002Fmicroliter.\n* 6.Liver transaminases (ALT and AST) \\\u003C=5 times upper limit of normal values (ULN); total bilirubin \\\u003C= 2 times ULN; creatinine clearance or eGFR \\> 50 mL\u002Fmin (either Cockcroft-Gault or MDRD is acceptable, whichever is higher).\n* 7.Subjects with chronic hepatitis B virus infection (HBV surface antigen (HBsAg) positive) must start antiviral therapy with nucleoside analogs (e.g., entecavir or tenofovir, according to current practice guidelines) before start of study drug treatment.\n\nExclusion Criteria:\n\n* 1.Major systemic diseases that the investigator considers inappropriate for participation.\n* 2.Any active autoimmune disease or history of known autoimmune disease except for vitiligo, resolved childhood asthma\u002Fatopy, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.\n* 3.Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol.\n* 4.Prior therapy with an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody (or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways).\n* 5.Requirement of systemic treatment with either corticosteroids (\\> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses \\> 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.\n* 6.Prior organ allograft or allogeneic bone marrow transplantation.\n* 7.Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation and in the judgment of the investigator would make the patient inappropriate for entry into this study.",{"count":568,"type":23},94,[62],"This is a prospective, double-blind, randomized, placebo-controlled trial to evaluate whether AHCC® (Active Hexose Correlated Compound) can enhance the effect of immunotherapy in liver cancer patients.",[572,573],"Liver Cancer","Hepatocellular Carcinoma",[575,576,577,578],"AHCC® (Active Hexose Correlated Compound)","immunotherapy","liver cancer","functional food","2025-08-07",{"date":581,"type":42},"2025-08-12",{"date":583,"type":23},"2025-08-20",{"date":465,"type":23},{"name":48,"class":49},{"id":587,"slug":588,"hasResults":12,"nctId":589,"briefTitle":590,"officialTitle":591,"acronym":4,"eligibilityCriteria":592,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":593,"enrollmentInfo":594,"targetDuration":4,"studyType":60,"phases":596,"briefSummary":597,"conditions":598,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":600,"lastUpdatePostDateStruct":601,"startDateStruct":603,"completionDateStruct":605,"leadSponsor":607,"locationsCount":103},"100496084","comprehensive-respiratory-training-exercise-program-in-obstructive-sleep-apnea-100496084","NCT05739617","Comprehensive Respiratory Training Exercise Program in Obstructive Sleep Apnea","Combining Sonography to Explore the Therapeutic Effect and Mechanism of a Comprehensive Respiratory Training Exercise Program on Cardiorespiratory Endurance and Airway Muscle Function in Obstructive Sleep Apnea","Inclusion Criteria:\n\n* Newly diagnosed with OSA (AHI≥ 5 events per hour)\n* Age between 20 to 65 years old\n* BMI of 18-30 kg.m-2\n\nExclusion Criteria: Diagnosed with any of the following diseases below:\n\n* Central or mixed types of sleep apnea\n* Neuromuscular disease\n* Severe cardiovascular disease\n* Active psychiatric disease\n* Head or neck disease or cancer\n* Structural abnormalities over the upper respiratory airway\n* Performed any operation or treatment over the neck before\n* Pregnancy","65 Years",{"count":595,"type":23},150,[62],"Obstructive sleep apnea (OSA) is a multi-factorial sleep disorder. Complete collapse or partial collapse in the airway increases the risk of developing cardiovascular and kidney-related disease in OSA patients. Resulting in an increase in medical expenses and workload for the healthcare worker. Multilevel of upper airway muscles especially the genioglossus muscle showed to contribute to airway obstruction as it fatigues easily. The endurance level of OSA patients was shown to be significantly lower. Therefore, the goal of this experimental study is to assess the feasibility and effectiveness of a comprehensive respiratory training exercise program on cardiorespiratory endurance, airway muscle function, and sleep parameters in patients with obstructive sleep apnea (OSA). Aside from exploring the therapeutic effect, the results of the study will be used to explore the mechanism of the treatment in relation to the changes in the OSA severity.",[599],"Obstructive Sleep Apnea of Adult","2025-06-15",{"date":602,"type":42},"2025-06-18",{"date":604,"type":42},"2023-03-01",{"date":606,"type":23},"2026-07-16",{"name":48,"class":49},""]